Non-invasive prescreening and drug efficacy evaluation, at scale.

Non-invasive prescreening and drug efficacy evaluation, at scale.

Non-invasive prescreening and drug efficacy evaluation, at scale.

Remote eye tracking is an optimal integration for neuropharma R&D in which iteration speed is impaired by existing slow & clunky hardware-based methods

Neuropharma

Elevate your trial success rates and unlock breakthrough treatments

Elevate your trial success rates and unlock breakthrough treatments

Elevate your trial success rates and unlock breakthrough treatments

Partner with us

Leverage our novel biometric diagnostic tools to improve therapeutic strategies.

Enhance Efficacy Demonstration

Enhance Efficacy Demonstration

  • Provides continuous, real-time monitoring of disease progression and treatment effects

  • Offers a comprehensive set of digital biometrics for nuanced disease assessment

  • Increases the sensitivity of outcome measurements in neuropharma trials

  • Provides continuous, real-time monitoring of disease progression and treatment effects

  • Offers a comprehensive set of digital biometrics for nuanced disease assessment

  • Increases the sensitivity of outcome measurements in neuropharma trials

Optimize Clinical Trial Screening

Optimize Clinical Trial Screening

  • Accelerates participant recruitment process, potentially shortening trial timelines

  • Lowers costs associated with participant screening and recruitment

  • Improves the quality and suitability of selected trial participants

  • Accelerates participant recruitment process, potentially shortening trial timelines

  • Lowers costs associated with participant screening and recruitment

  • Improves the quality and suitability of selected trial participants

"To date, we’ve used the MMSE and MoCA as a proxy for cognitive health in our liquid Donepezil drug trials. We found that the quantitative results they provide lack a degree of specificity crucial for the statistical rigor we uphold at Brio - which Vytal is able to deliver."

— COO, Brio Pharmaceuticals

Current State of Neuropharma

Current State of Neuropharma

Current State of Neuropharma

New drug development costs exceed

New drug development costs exceed

New drug development costs exceed

$2 Billion

$2 Billion

Alzheimer's disease trials often have screen failure rates ranging from

Alzheimer's disease trials often have screen failure rates exceeding

Alzheimer's disease trials often have screen failure rates ranging from

70 - 80%​

70%​

70 - 80%​

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data is

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data exceeds

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data is

40 - 50%

40%

40 - 50%

Neurology Phase 1 approval likelihood is

Neurology Phase 1 approval likelihood is

Neurology Phase 1 approval likelihood is

Just 5.9%

Just 5.9%

Eye movement biometrics can be used to evaluate:

Eye movement biometrics can be used to evaluate:

Eye movement biometrics can be used to evaluate:

Traumatic Brain Injury
Stroke
Alzheimer's Disease
ADHD
Parkinson’s Disease
Schizophrenia

We Integrate It For You

Our team can integrate our solutions into your existing software, or, if necessary, build software completely tailored to your needs. 

We focus on helping you attain measurable outcomes, demonstrating the positive impact of Vytal’s solutions on your business’s productivity.

The Future Of Eye Tracking and Brain Health

The Future Of Eye Tracking and Brain Health

The Future Of Eye Tracking and Brain Health

"To date, we’ve used the MMSE and MoCA as a proxy for cognitive health in our liquid Donepezil drug trials. We found that the quantitative results they provide lack a degree of specificity crucial for the statistical rigor we uphold at Brio - which Vytal is able to deliver."

— COO, Brio Pharmaceuticals

"To date, we’ve used the MMSE and MoCA as a proxy for cognitive health in our liquid Donepezil drug trials. We found that the quantitative results they provide lack a degree of specificity crucial for the statistical rigor we uphold at Brio - which Vytal is able to deliver."

— COO, Brio Pharmaceuticals